

## UCARTMESO: Mesothelin (MSLN) targeting allogeneic CAR-T cells engineered to overcome tumor immunosuppressive microenvironment

**Roman Galetto<sup>1</sup> and Agnès Gouble<sup>1</sup>.** 

<sup>1</sup> Cellectis SA, 8 Rue de la Croix Jarry, 75013, Paris, FRANCE

#### INTRODUCTION

- Chimeric antigen receptor (CAR) T cell therapy has provided a new therapeutic option to patients with B cell malignancies, but has thus far not shown consistent therapeutic benefit in solid tumors
- New approaches to address the challenges that have limited the efficacy of CAR-T cell therapy in solid are emerging, as preventing immune suppression in the tumor microenvironment (TME)
- Factors present in the TME can impair CAR-T cell activity, with TGFB being one of the most important regulators
- UCARTMESO is an allogeneic CAR-T cell product that targets mesothelin (MSLN) expressing cells, gene engineered to circumvent immune suppressive signals from the TME
- UCARTMESO pre-clinical currently under İS development by Cellectis
- 5 TGFβR2-EDITED MESOCAR-T CELLS DISPLAY POTENT ANTI-TUMOR ACTIVITY IN VITRO AND IN VIVO In vitro Killing of MESO+ cells Tumor cell H226 cell killing 80-60-MESO CAR-T cell 🥵 1:3 1:1 3:1 CAR-T cells : MESO+ cells ratio In vivo Killing of MESO+ cells --- vehicle --- 1x10<sup>6</sup> CAR<sup>+</sup> cells 1x10<sup>6</sup> CAR+ cells 3x10<sup>6</sup> CAR+ cells Day 7 🌉 ′ 10<sup>8</sup>-<sup>2</sup> 10<sup>7</sup> Day 14

This communication expressly or implicitly contains certain forward-looking statements concerning Cellectis and its business. Cellectis is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This communication contains Cellectis' proprietary information. TALEN® and Cellectis® are trademarks owned by the Cellectis Group.


CAR T-cell

Day 21

# Cécile Schiffer-Mannioui<sup>1</sup>, Sophie Leduc<sup>1</sup>, Isabelle Chion-Sotinel<sup>1</sup>, Diane Le Clerre<sup>1</sup>, Valérie Guyot<sup>1</sup>, Marco Rotondi<sup>1</sup>,



### MESOTHELIN IS AN ATTRACTIVE SOLID TUMOR TARGET




## Mesothelin (MSLN):

- Cell-surface antigen overexpressed in a a wide range of solid tumors
- One of the most studied targets for solid tumor treatment
- Promising preliminary clinical results have been reported using MSLN-targeted agents


- TGFβR2-KO MESOCAR-T cells display *in vitro* cytotoxic activity against H226 cells (a mesothelioma cell line expressing MSLN and able to produce TGF $\beta$ )
- Killing efficacy is proportional to the dose of CAR-T cells
- Cells were also able to secrete IFN $\gamma$  and proliferate in response to antigenic stimulation *in vitro* (not shown)



- In vivo activity of TGF $\beta$ R2-KO MESOCAR-T cells was evaluated in immunodeficient mice harboring a mesothelioma tumor model
- H226 tumor burden was confirmed by bioluminescence imaging 13 days after intrapleural injection of H226 cells (Day -1 of treatment)
- IV infusion of vehicle or CAR-T cells was administered at Day 0
- Tumor regression (and increased survival) was observed in all **CAR-T treated animals**
- Tumors were almost undetectable at the dose of 3x10<sup>6</sup> CAR-T cells at the end of study (Day 70)



- In a TGF $\beta$  deprived TME, recognition of MSLN+ cells by CAR-T cells induces their activation
- In a TGF $\beta$  rich tumor microenvironment, binding of TGF $\beta$  to its receptor (expressed at the CAR-T cell surface) leads to inhibition of CAR-T cell activation
- CAR-T cells exposed to tumor antigen in the presence of TGFB display decreased expression of IL2 receptor (CD25) suggesting that these CAR-T cells could have impaired cell expansion and <u>survival</u>




UCARTMESO product candidate is composed of allogeneic nonalloreactive T cells edited with TALEN<sup>®</sup>-encoding mRNAs to disrupt TRAC, CD52 and TGF $\beta$ R2 genes, and transduced ex vivo with a rLV to express a second-generation CAR targeting MSLN

- $\circ$  TCR $\alpha$  gene KO minimizes the occurrence of GvHD
- CD52 gene KO improves persistence of UCARTMESO in the presence of alemtuzumab (an anti-CD52 mAb that can be used as lymphodepleting agent)
- $\circ$  TGF $\beta$ R2 gene KO protects UCARTMESO from the inhibitory effect of TGFβ



#### TGFBR2 EDITED CAR-T CELLS ARE RESISTANT TO TGF $\beta$

4



- The inhibitory effect of TGF $\beta$  on CAR-T cells can be counteracted by knocking-out its receptor: the TGFBR2 gene
- TGF $\beta$ R2 edited CAR-T cells can be activated whether in the absence or presence of TGF $\beta$
- TGFBR2-KO MESOCAR-T cells exposed to tumor antigen in the presence of TGF<sup>β</sup> show strong expression of IL2 receptor, suggesting they have <u>normal cell expansion and survival</u>

#### **CONCLUSIONS & PERSPECTIVES**

- Solid tumors have presented a challenge to the success of adoptive cellular therapies, due at least in part to the immunosuppressive tumor microenvironment
- Mesothelin is an attractive target for CAR-T cell therapy in solid tumors as it is overexpressed on a wide variety of tumors types
- UCARTMESO is an allogeneic "off-the-shelf" product candidate that incorporates, TCR $\alpha$ -KO, CD52-KO, and TGF $\beta$ R2-KO, and expresses a 2<sup>nd</sup> Generation MSLN-CAR
- TGF $\beta$ R2-KO MESOCAR-T cells are unable to transduce inhibitory signals through the TGF $\beta$  pathway, and therefore capable of responding to antigen stimulation in the presence of TGF $\beta$
- Preclinical studies show potent activity of UCARTMESO in vitro and in vivo against MSLN expressing cell lines
- In vivo activity has been confirmed in pancreatic and pleural mesothelioma mouse models
- **TGF**βR2 gene KO provides valuable additional properties to UCARTMESO, representing a very attractive strategy for their use in the treatment of solid tumors